Syndax Pharmaceuticals (NASDAQ:SNDX) Sets New 1-Year Low – What’s Next?

Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDXGet Free Report) reached a new 52-week low during trading on Thursday . The stock traded as low as $15.00 and last traded at $15.27, with a volume of 786132 shares changing hands. The stock had previously closed at $15.95.

Analyst Ratings Changes

SNDX has been the subject of a number of recent research reports. Citigroup increased their price target on shares of Syndax Pharmaceuticals from $37.00 to $45.00 and gave the stock a “buy” rating in a research note on Tuesday. Barclays raised their price target on Syndax Pharmaceuticals from $32.00 to $33.00 and gave the stock an “overweight” rating in a report on Thursday, August 15th. HC Wainwright upped their price objective on Syndax Pharmaceuticals from $49.00 to $51.00 and gave the company a “buy” rating in a research note on Monday. Bank of America increased their price objective on Syndax Pharmaceuticals from $30.00 to $31.00 and gave the stock a “buy” rating in a research report on Thursday, August 15th. Finally, JPMorgan Chase & Co. boosted their target price on Syndax Pharmaceuticals from $33.00 to $38.00 and gave the company an “overweight” rating in a report on Thursday. Two equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $37.64.

View Our Latest Stock Report on SNDX

Syndax Pharmaceuticals Trading Down 0.7 %

The firm has a market cap of $1.35 billion, a PE ratio of -4.16 and a beta of 0.92. The company has a 50 day moving average price of $18.71 and a 200 day moving average price of $20.08.

Syndax Pharmaceuticals (NASDAQ:SNDXGet Free Report) last posted its earnings results on Tuesday, November 5th. The company reported ($0.98) EPS for the quarter, topping analysts’ consensus estimates of ($1.13) by $0.15. The firm had revenue of $12.50 million for the quarter, compared to analysts’ expectations of $9.16 million. During the same quarter in the previous year, the firm posted ($0.73) earnings per share. As a group, equities research analysts anticipate that Syndax Pharmaceuticals, Inc. will post -3.69 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Syndax Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in SNDX. Vanguard Group Inc. grew its position in shares of Syndax Pharmaceuticals by 13.6% in the first quarter. Vanguard Group Inc. now owns 4,926,984 shares of the company’s stock valued at $117,262,000 after purchasing an additional 591,631 shares during the last quarter. State Street Corp lifted its stake in Syndax Pharmaceuticals by 4.1% in the 3rd quarter. State Street Corp now owns 3,770,826 shares of the company’s stock valued at $72,588,000 after buying an additional 148,491 shares in the last quarter. Sofinnova Investments Inc. grew its holdings in Syndax Pharmaceuticals by 33.9% during the 2nd quarter. Sofinnova Investments Inc. now owns 2,153,669 shares of the company’s stock valued at $44,215,000 after buying an additional 545,129 shares during the last quarter. Geode Capital Management LLC increased its position in Syndax Pharmaceuticals by 3.5% during the third quarter. Geode Capital Management LLC now owns 1,977,082 shares of the company’s stock worth $38,066,000 after buying an additional 66,459 shares in the last quarter. Finally, First Turn Management LLC raised its holdings in shares of Syndax Pharmaceuticals by 85.4% in the third quarter. First Turn Management LLC now owns 1,187,165 shares of the company’s stock worth $22,853,000 after acquiring an additional 546,776 shares during the last quarter.

Syndax Pharmaceuticals Company Profile

(Get Free Report)

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).

Featured Stories

Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.